

Resources to Address Potential Barriers to Long-Acting Injectable Antiretroviral (L-AI ARV) Therapy

Please use the <u>NASTAD Cabenuva Considerations for AIDS Drug Assistance Programs</u> and the <u>ViiVConnect</u> site for the latest industry information. Please note the latest dosing guidelines here: <u>Cabenuva Dosing and</u> Admin Guide PDF Jan 2022.pdf (cabenuvahcp.com).

Based on Ryan White provider feedback on potential barriers to L-AI ARVs, we have gathered the following resources, suggestions, and best practices.

Patient Adherence Issues:

Area of concern	Suggestions and best practices
Problems with	Use overbook appointment spots or walk-in appointment spots as a failsafe on
tracking patient follow-up	rescheduled appointments.
	A best practice is to create a spreadsheet to track patients on Cabenuva (and shipments) when current appointment systems are unable to set up reminders and follow-up appointments (or flag Cabenuva users).
	Costs & Resources provides Cabenuva-specific support services for providers and clients.
	Once your doctor prescribes Cabenuva, you can be enrolled in ViiVConnect to get support.
Problems with drug delivery	Contact your SPECIALTY PHARMACY for lost and delayed shipments, damaged or unusable medications due to shipping, broken vials noted on or right after delivery, or indications that temperature has not been maintained during shipping.
	For accidental breakage of vial and product replacement scenarios, contact GSK Pharma Service Center at 1-800-877-1158, Option 4, M–F 8:00 a.m.–8:00 p.m. ET.
	For particulate matter or product discoloration scenarios, contact GSK Response Center at 1-888-825-5249, M–F 8:30 a.m.–5:30 p.m. ET.
	For medication access issues not listed above, contact a ViiV field reimbursement manager for further guidance:
	 For North and Central Florida, contact Marvin Poole, FRM, at
	Marvin.x.poole@viivhealthcare.com or 407-516-0534.
	 For Orlando and North Florida, contact Barbara Pope, FRM, at
	barbara.k.pope@viivhealthcare.com or 516-522-8463.
	 For Palm Beach (south of Jupiter Inlet), Miami-Dade, Monroe, and Broward, contact Andrea Spaulding, FRM, at: <u>andrea.n.spaulding@viivhealthcare.com</u> or 561-222-3489.



Resources to Address Potential Barriers to Long-Acting Injectable Antiretroviral (L-AI ARV) Therapy

Oral medication	For optional initial oral lead in , a practitioner would place order for initiation of Cabenuva through <u>Provider Resources ViiVConnect</u> . A prescription needs to be sent to TheraCom for Vocabria (cabotegravir) and Edurant (rilpivirine).
	For planned missed injection , the current process is to contact <u>ViiVConnect</u> to get information to send the prescription to TheraCom for Vocabria (the cabotegravir portion of the oral medication). The Edurant (rilpivirine) portion of the oral regimen is available for order at the client's retail pharmacy.

Staff Training Issues:

Area of concern	Suggestions and best practices
	Suggestions and best practices
Staff training	There is an updated dosing and administration guideline with infographics available at
specific to	Cabenuva Dosing and Admin Guide PDF Jan 2022.pdf (cabenuvahcp.com).
Cabenuva and Z-	
track injection	
Possible issues	Clinical support staff should be made aware of the +/- seven-day window limitation to
with rescheduling	schedule for Cabenuva injections. Include front desk staff in training on the importance of
appropriately for	rescheduling patients receiving Cabenuva in a timely manner.
the injection	
	If a patient cannot be reached or cancels their appointment, refer to internal processes
	and include seeking county health department support to locate the patient (through a
	linkage and engagement specialist or disease intervention specialist).
Clinical	DO NOT TAKE THE MEDICATION OUT OF THE FRIDGE UNTIL THE PATIENT
considerations	ARRIVES. Please wait 15 minutes for the medication to warm up at room temperature
for Cabenuva	prior to injection administration.
temperature	
control and	If you need a larger administration needle to accommodate for body size, contact Fisher
administration	Healthcare for the two-inch safety needle. Search for "2-inch safety needle."

Transportation Issues:

Area of concern	Suggestions and best practices
Transportation access and limited ability to present to clinic	Local areas are to determine how to address transportation needs within their jurisdictions. Transportation issues are not unique to this drug and are handled differently in different areas based on available resources.
for follow-up	Consider ride-share services available in your area. Other possible transportation services may be available through local volunteer organizations, elder care services organizations, and community and religious centers.



Resources to Address Potential Barriers to Long-Acting Injectable Antiretroviral (L-AI ARV) Therapy

Medication Costs:

Area of concern	Suggestions and best practices
Coverage for	Please see the cost sharing and patient assistance information on NASTAD Cabenuva
those not eligible	Considerations for AIDS Drug Assistance Programs.
for the AIDS Drug Assistance	The Patient Assistance Program (PAP) CANNOT BE USED IF THE CLIENT IS ON
Program (ADAP)	ADAP.
	To be eligible for PAP, the patient MUST:
	Live in one of the 50 states, the District of Columbia, or Puerto Rico
	 Have a household income less than or equal to 500 percent of the Federal Poverty Level based on household size
	 Not be eligible for Medicaid or Puerto Rico's Government Health Plan, Mi Salud Meet one of the following:
	Have no prescription drug coverage
	 Have a Medicare Part B, Medicare Part D, or Medicare Advantage Plan and have spent at least \$600 on out-of-pocket prescription expenses during the current calendar year
	Have a private insurance plan limited to generic-only coverage, outpatient use only, or therapeutic class exclusion (non-coverage) of drug
	The PAP decision will be provided after all information is confirmed.
	The PAP is in Section 8 of the <u>Enrollment Form</u> .

Billing:

Area of concern	Suggestions and best practices
Administration costs	Administration costs for the Cabenuva injection range from \$20 to \$25.08 based on current Medicare rates.
	Associated billing code for Cabenuva:
	CPT injection code 96372 for each intramuscular injection provided by a nurse under the direct supervision of a provider
	HCPCS J0741: Injection, cabotegravir and rilpivirine, 2mg/3mg
	(Medicaid has an automated prior authorization)